APM Overview

Aptorum Group Limited is a United Kingdom-based clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.

Wall Street analysts forecast APM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for APM is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aptorum Group Ltd revenue for the last quarter amounts to NaN USD, decreased

Aptorum Group Ltd. EPS for the last quarter amounts to USD, decreased

Aptorum Group Ltd (APM) has 1 emplpoyees as of March 21 2026.

Today APM has the market capitalization of 7.63M USD.